×ðÁú¿­Ê±

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ £¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
News information
ÐÂÎÅ×ÊѶ

ÁÖÇì´Ï²©Ê¿Ïê½â¡°¾íÍõADC¡±µÄÁÙ´²Ç°Çå¾²ÐÔÆÀ¼ÛÐèҪ˼Á¿Ê²Ã´£¿

2024-05-09
|
»á¼ûÁ¿£º

APPLIED-PHARMACEUTICAL-TOXICOLOGY-(APT)-2024.jpg

2024Äê5ÔÂ14-16ÈÕ £¬APPLIED PHARMACEUTICAL TOXICOLOGY (APT) 2024 ½«ÔÚMerck Research Laboratories, Boston, MA¾ÙÐС£×ðÁú¿­Ê±Ö´Ðи±×ܲüæÃÀ¹ú¹«Ë¾×ܲÃÁÖÇì´Ï²©Ê¿ÊÜÑû³öϯ´Ë´Î¾Û»á £¬²¢½ø´øÀ´¡° Preclinical Safety Evaluation for Antibody Drug Conjugates (ADCs)¡±¾«²ÊÑݽ² £¬Õ¹Ê¾×ðÁú¿­Ê±ADCһվʽÑз¢Ð§ÀÍÄÜÁ¦¡£

ͬʱ £¬×ðÁú¿­Ê±ÃÀ¹úÍŶÓÒ²ÁÁÏàÏÖ³¡ £¬Í¨¹ýÏÖ³¡Õ¹Ì¨»¥¶¯µÈ·½·¨ºÍÈ«ÇòADCÐÐÒµ´ó¿§¾ÙÐÐÉîÈë½»Á÷ºÍ̽ÌÖ £¬Ò»Á¬¸³ÄÜÐÐÒµ £¬¼ÓËÙADCÒ©ÎïÑз¢Àú³Ì¡£

×ðÁú¿­Ê±ÔÚADCÁìÓòÉî¸û¶àÄê £¬ÓµÓÐÂÄÀú¸»ºñµÄÊÖÒÕÍŶӺͺϳÉÂÄÀú £¬¹¹½¨Á˸»ºñ¶àÑùµÄADC¿â¡£×èÖ¹2024Äê4Ô £¬×ðÁú¿­Ê±ÒÑÀÖ³ÉÖúÁ¦24¸öADCÒ©Îï»ñÅúÁÙ´² £¬²¢Óжà¸öADCÏîÄ¿ÔÚÑС£½Ó´ýÒµÄÚͬÈʽìʱÓë»á½»Á÷£¡

ʱ¼ä | 5ÔÂ14-16ÈÕ
ËùÔÚ | Merck Research Laboratories, Boston, MA
×ðÁú¿­Ê±Õ¹Î»#3 £¬²»¼û²»É¢£¡

×ðÁú¿­Ê±Ö´Ðи±×ܲüæÃÀ¹ú¹«Ë¾×ܲÃÁÖÇì´Ï²©Ê¿.jpg

APPLIED-PHARMACEUTICAL-TOXICOLOGY-(APT)-2024-¾Û»áÒé³Ì.jpg

×ðÁú¿­Ê±ADCÒ©ÎïÑз¢Ð§ÀÍÆ½Ì¨

×ðÁú¿­Ê±ÔÚADCµÄÁÙ´²Ç°Ò»Ì廯Ñо¿¼Æ»®Öƶ©ÖÐÓë¿Í»§ÉîÈë½»Á÷ £¬¿ÆÑÐÖ÷¸É½«Ã¿Ò»¸ö°¸ÀýµÄÌØµãÓë¶àÄêʵսÂÄÀúºÍÊÖÒÕ»ýÀÛÏàÁ¬Ïµ £¬ÉóÉ÷µØ½«ÓÅÖÊʵÑ鼯»®ÓëЧ¹ûÌá½»µ½¿Í»§ÊÖÉÏ¡£×ðÁú¿­Ê±¿ÉÒÔΪ¿Í»§ÌṩADC PayloadsºÏ³É¡¢ADCÒ©ÎïżÁª¡¢ADCҩЧѧÆÀ¼Û¡¢ADCÒ©´ú¶¯Á¦Ñ§ÆÀ¼ÛºÍADCÇå¾²ÐÔÆÀ¼ÛµÈЧÀÍ¡£×èÖ¹ÏÖÔÚ £¬×ðÁú¿­Ê±³Ð½ÓµÄINDÉ걨ÀàÉúÎïÒ©´óÏîÄ¿ÒѾ­100¶àÏî £¬°üÀ¨µ¥¿¹¡¢Ë«¿¹¡¢¶à¿¹¡¢ADC¡¢²¡¶¾ÒßÃçºÍÈÚºÏÂѰ׵È¡£

×ÉѯЧÀÍ

ADC LinkersÏÖ»õ²úÆ·

ÖþÒ©ÍøÊÇADCÏà¹Ø²úÆ·¶¨ÖƺÍЧÀ͹©Ó¦ÉÌ £¬ÓµÓÐR&DʵÑéÊҺ͸߻îÐÔÒ©ÎïÉú²úÄÜÁ¦ £¬¿ÆÑÐÍŶÓÓµÓÐרҵ¸»ºñµÄ»¯Ñ§ÐÞÊÎÊÖÒÕºÍÄÜÁ¦ £¬ÔÚ¿â¶¾ËØºÍÅþÁ¬×Ó¿ÉÒÔΪ¿Í»§Öª×ã´ÓºÁ¿Ëµ½Ç§¿Ë¼¶Ñз¢ÐèÇó £¬ÊµÏÖ´ÓÒ©ÎïÑз¢¹âÁÙ´²Ç°CMCÉú²úµÄÈ«Àú³ÌЧÀÍ £¬½µµÍÑз¢±¾Ç® £¬Ìá¸ßÒ©ÎïÑз¢ËÙÂʺÍЧÂÊ¡£

Ñ¡¹º²úÆ·

ADC
Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿